<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202395</url>
  </required_header>
  <id_info>
    <org_study_id>LTS-201-P1.0</org_study_id>
    <nct_id>NCT02202395</nct_id>
  </id_info>
  <brief_title>Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate</brief_title>
  <acronym>T8</acronym>
  <official_title>A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pharmaceuticals Holding Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pharmaceuticals Holding Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of Hydroxytriptolide(LTS)
      in active rheumatoid arthritis patients with an inadequate response to methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Investigate the efficacy of Hydroxytriptolide in active RA patients

        2. Investigate the safety of Hydroxytriptolide in active RA patients. Especially in female
           reproductive system.

        3. Population PK study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 28, 2016</completion_date>
  <primary_completion_date type="Actual">April 30, 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ACR 20 at 12 weeks and at 24 weeks</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in DAS 28 at 12 weeks and at 24 weeks</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients reached ACR50 at 12 weeks and 24 weeks</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients reached ACR70 at 12weeks and 24weeks</measure>
    <time_frame>12weeks,24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in swollen joint count at 12 weeks and 24 weeks</measure>
    <time_frame>12weeks,24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in tender joint count at 12weeks and 24weeks</measure>
    <time_frame>12weeks,24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the duration of morning stiffness at 12 weeks and 24 weeks</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in rest pain at 12 weeks and 24 weeks</measure>
    <time_frame>12weeks,24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PtGA patient global assessment at 12 weeks and 24 weeks</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PGA physician global assessment at 12 weeks and 24 weeks</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HAQ health assessment questionnaire at 12 weeks and 24 weeks</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CRP,ESR,RF,CCP at 12 weeks and 24 weeks</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IgA, IgG, IgM at 12 weeks and 24 weeks</measure>
    <time_frame>12 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>0.25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTS 0.25mg,qd MTX qw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTS 0.5mg, qd MTX qw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LTS 1.0mg,qd MTX qw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo qd MTX qw</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTS 0.25mg</intervention_name>
    <description>use LTS 0.25mg/d</description>
    <arm_group_label>0.25mg</arm_group_label>
    <other_name>Hydroxytriptolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTS 0.5mg</intervention_name>
    <description>use LTS 0.5mg/d</description>
    <arm_group_label>0.5mg</arm_group_label>
    <other_name>Hydroxytriptolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTS 1.0mg</intervention_name>
    <description>use LTS 1.0mg/d</description>
    <arm_group_label>1.0mg</arm_group_label>
    <other_name>Hydroxytriptolide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>use placebo once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  35-65 years old, female, postmenopausal, parous, nulliparous with no fertility
             requirements

          -  1987 ACR Diagnostic criteria or 2009 ACR/EULAR Diagnostic criteria. X ray of Evaluable
             Joint in phase I/II/III, Joint Function in Phase I/II/III

          -  Active RA

          -  Continuously taking MTX for at least three months, ≥7.5mg/week. Before first study
             dose, keep in stable MTX dose for at least 4 weeks

          -  Keep in stable NSAIDs dose or low-dose glucocorticoids for at least 4 weeks before
             first study dose

          -  Using non-prohibited combination therapy, keep in stable dose for at least 7 days
             before first study dose

          -  Using DMARD should have appropriate withdrawal period:

               -  Withdrawal for 4 weeks: Sulfasalazine, Azathioprine, Chloroquine,
                  *Hydroxychloroquine, Auranofin, Penicillamine, Traditional Chinese medicine
                  preparation(TGP, Sinomenine)

               -  Withdrawal for 8 weeks: Leflunomide

               -  Withdrawal for 8 weeks: Intramuscular, intravenous, intra-articular injection
                  glucocorticoids

          -  Women with fertility, negative in pregnancy test, and agreed to take contraceptive
             measures physical

          -  Voluntary informed consent

          -  Willing to follow the required regimen and schedule, follow-up examination

        Exclusion Criteria:

          1. Currently suffering or have suffered from other inflammatory joint diseases, such as
             mixed connective tissue disease, scleroderma, systemic lupus erythematosus, ankylosing
             spondylitis, psoriatic arthritis, Reiter's syndrome, bone arthritis, rheumatoid
             arthritis, gouty arthritis, diagnosis of arthritis before 16yrs

          2. With severe non-articular manifestations such as high fever, interstitial pneumonia,
             pleurisy, pericarditis, severe vasculitis, neuropathy, etc.

          3. The evaluable joint underwent the surgical treatment within 2 months

          4. Currently or recent have serious, or progression, or disease history not controled,
             including: liver, kidney, blood, gastrointestinal, endocrine, metabolic, respiratory,
             cardiovascular, nervous system diseases

          5. Currently or have malignancy, lymphoproliferative disease history

          6. Continuously use Tripterygium preparations for more than three months and have no
             effect

          7. History of using TNF-a inhibitors of biological agents.(Adalimumab, infliximab,
             etanercept)

          8. Severe or persistent infection within 3 months

          9. X-ray shows active pulmonary infection

         10. HBV, HCV, HIV, AIDS

         11. WBC&lt;4.0×10^9/L, PLT&lt;100×10^9/L, Hb&lt;85g/L

         12. AST&gt;2×ULN, ALT&gt;2×ULN

         13. Cr&gt;135umol/L

         14. Used oral contraceptive druds within 3 months

         15. Pregnancy test was positive or lactating patients or patients with birth preparation

         16. Have to use the prohibited drugs

         17. With clinical symptoms of a serious history of drug abuse or alcohol abuse

         18. History of any durg clinical trials within 3 months

         19. Allergy to tripterygium

         20. Other reasons depends by the investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunde Bao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The first affiliated hospital of bengbu medical college</name>
      <address>
        <city>Bengbu</city>
        <state>Anhui</state>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>June 2, 2017</last_update_submitted>
  <last_update_submitted_qc>June 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydroxytriptolide</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>T8</keyword>
  <keyword>LTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

